The Caring Corner®
New FDA Guidelines May Speed Alzheimer’s Drug Development
The challenge with currently approved Alzheimer’s drugs, developed when much less was known about the disease, is that they help mitigate the symptoms, but do little to reverse or correct the underlying cause. The New England Journal of Medicine this week outlined new guidelines for drug developers that may over time improve the speed of getting new drugs to market.
It is widely accepted that the development of Alzheimer’s is directly linked to the presence of amyloid plaques and neurofibrillary tangles in the brain. The new drug development guideline will allow pharmaceutical companies to develop drugs that are seen to reduce these, without necessarily having impact on cognitive ability. Good news for anyone who suffers from this disease, and perhaps even more so for those of us who (due largely to age) are candidates for it in the future. Read more in this article.
